Predictive Oncology Partners with Switzerland-Based Tecan Group Ltd. to Expand High-Throughput Drug Screening to Include Human Tumor Spheroids Using Automated Imaging and 3D Analysis
Rhea-AI Summary
Predictive Oncology (NASDAQ: POAI) announced positive results from a collaborative study with Tecan, at the 2025 SLAS International Conference. The study focused on utilizing patient-derived tumor spheroids (PDTS) from POAI's biobank of cryopreserved tumor specimens for drug screening.
The research demonstrated successful transition from 2D cell culture to cryopreservation and then to 3D cell culture, using breast, colon, and ovary samples with known drug response data. The collaboration leverages Tecan's SparkCyto instrument and 3DAI software for automated analysis of tumor spheroids.
This advancement addresses a key challenge in cancer research: the accessibility and scalability of primary tumor cells. The high-throughput screening market is projected to reach $69.5 billion by 2032, with a CAGR of 12.18%, according to SNS Insider research.
Positive
- Successfully demonstrated viable transition from 2D to 3D cell cultures using cryopreserved tumor specimens
- Operating in high-growth market projected to reach $69.5B by 2032 (12.18% CAGR)
- Partnership with established player Tecan enhances technological capabilities
Negative
- None.
Insights
This partnership marks a pivotal advancement in drug screening technology that significantly strengthens POAI's market position. The integration of Tecan's SparkCyto instrument and 3DAI software with POAI's extensive biobank creates a powerful platform for drug discovery that addresses key industry challenges.
The technical breakthrough lies in the successful preservation and transition of tumor cells from 2D to 3D cultures. Traditional 2D cell cultures often fail to replicate the complex tumor microenvironment, leading to poor predictability in drug development. The ability to maintain viable dissociated tumor cells (DTCs) through cryopreservation while enabling their growth into 3D spheroids represents a significant competitive advantage in the $69.5 billion high-throughput screening market.
This development has three major commercial implications:
- Enhanced drug discovery efficiency through more physiologically relevant screening models
- Improved predictability of drug responses, potentially reducing late-stage clinical trial failures
- Expanded capabilities in personalized medicine through patient-specific tumor models
The collaboration with Tecan, a respected Swiss laboratory automation company, validates POAI's technology and positions them to capture a larger share of the growing high-throughput screening market. The 12.18% CAGR projection suggests strong industry demand for advanced screening technologies, particularly those enabling 3D cell culture applications.
Study used Predictive Oncology’s vast biobank of cryopreserved live cell tumor specimens for the production and testing of primary patient tumor spheroids
Results presented at the 2025 Society for Laboratory Automation and Screening (SLAS)
PITTSBURGH, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from an ongoing study in collaboration with Switzerland-based Tecan, Ltd. were recently presented at the 2025 Society for Laboratory Automation and Screening (SLAS) International Conference & Exhibition, which was held January 25-29, 2025, in San Diego, CA.
Cancer research increasingly relies on patient-derived tumor models (PDTMs), such as patient-derived tumor spheroids (PDTS), to develop personalized therapies as they offer a more physiologically relevant system, preserving the morphology, cellular complexity, and microenvironment of corresponding tissues. A key challenge of utilizing PDTS is the accessibility and scalability of primary tumor cells. The use of cryopreserved dissociated tumor cells (DTCs) which are single cell suspensions dissociated from solid tumors addresses this limitation, and offers a robust method to store and culture viable DTCs for research.
Optimized growth conditions and drug treatment protocols were established for tumor models derived from cryopreserved DTCs of different cancer types. 3D models are closer to in vivo physiological conditions than 2D models, and as expected, differences in response to drug dosing are observed.
“The capability to obtain a tumor specimen and monitor its growth and drug response as it transitions from a 2D cell culture to cryopreservation and then to a 3D cell culture significantly enhances the relevance and availability of our samples for high-throughput drug discovery, personalized medicine, and biomarker discovery,” said Dr. Arlette Uihlein, Senior Vice President of Translational Medicine and Drug Discovery and Medical Director at Predictive Oncology. “The breast, colon and ovary samples used to generate primary patient spheroids were selected from the Predictive Oncology biobank. All samples were chosen based on known drug response data indicating responsiveness to the clinically relevant compounds used in this study.”
The high throughput screening [HTS] market is projected to reach
A major obstacle to the use of patient-derived tumor spheroids in research and drug development is the limited accessibility and scalability of primary tumor cells. This challenge is mitigated by the utilization of cryopreserved dissociated tumor cells (DTCs), which represent a scalable resource for experiments with viable primary tumor material.
“This process requires precise monitoring and characterization, including multiple imaging techniques and viability assessments to evaluate tumor growth and drug response. The studies presented in this poster summarize recent developments in the use of the POAI biobank for optimizing the use of DTCs, by multiplexing label-free artificial intelligence based automated analysis of tumor spheroids over time with real-time drug dose response,” said Eric Lutsch, Application Scientist at Tecan, Austria. “The spheroids were evaluated using the Tecan SparkCyto instrument and 3DAI software capabilities.”
About Tecan
Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,500 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2023, Tecan generated sales of CHF 1,074 million (USD 1,194 million; EUR 1,108 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with
Investor Relations Contact:
Tim McCarthy
LifeSci Advisors, LLC
tim@lifesciadvisors.com
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward- looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the company disclaims any intent or obligation to update these forward-looking statements.
FAQ
What are the key findings of POAI's collaboration with Tecan presented at SLAS 2025?
How large is the market opportunity for POAI's high-throughput screening technology?
What types of cancer samples did POAI use in their Tecan collaboration study?
How does POAI's technology address the scalability challenge in tumor research?
What technology is being used to analyze the tumor spheroids in POAI's research?
